GNPX News and Press, Genprex Inc. From 05/30/23

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer PR Newswire Results from Phase 1 Portion Indicate Favorable Safety P...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is reporting on positive data gathered from the phase 1 portion of its Acclaim-1 clinical trial. The trial is designed to evaluate the company’...

Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting PR Newswire Results Show Combination of REQORSA® and Tagrisso® was Well...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video where the company's Chief Medical Officer Mark Berger, MD discusses the recently presented positive preclinical data for...

Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System PR Newswire Chief Medical Officer Provides Overview of Preclinical Data Recently Presented at ...

Positive preclinical data was presented for the NPRL2 tumor suppressor gene The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models V...

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced its participation in upcoming industry and investor conferences to be held in May 2023. These include the Sidoti Micro...

Genprex to Participate and Present at Upcoming May Industry and Investor Conferences PR Newswire Presentations to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 8, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "C...

2023-04-24 10:08:54 ET Gainers: IN8bio ( INAB ) +121% . IDEAYA Biosciences ( IDYA ) +27% . ZyVersa Therapeutics ( ZVSA ) +26% .  Koninklijke Philips ( PHG ) +15% . Kiora Pharmaceuticals ( KPRX ) +9% . Losers: Scilex H...

2023-04-24 08:20:02 ET Presto Automation ( PRST ) -16% . Jayud Global Logistics Limited ( JYD ) -14% . Wang & Lee Group ( WLGS ) -13% . Satixfy Communications ( SATX ) -10% . Onconova Therapeutics ( ONTX ) -9% . C3.ai ( AI ...